Compare CALC & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | WIMI |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 22.2M |
| IPO Year | 2020 | 2019 |
| Metric | CALC | WIMI |
|---|---|---|
| Price | $2.03 | $1.15 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 290.4K | 92.2K |
| Earning Date | 05-13-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $1.07 |
| 52 Week High | $7.20 | $5.65 |
| Indicator | CALC | WIMI |
|---|---|---|
| Relative Strength Index (RSI) | 73.58 | 33.35 |
| Support Level | $0.53 | $1.07 |
| Resistance Level | $2.47 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 78.22 | 3.12 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.